CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Pyronaridine-ArtesunateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug2367 Study A Wiki 1.00
drug2371 Study D Wiki 1.00
drug2370 Study C Wiki 1.00
drug2369 Study B Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.

NCT04475107 COVID-19 Drug: Pyronaridine-Artesunate Drug: Placebo

Primary Outcomes

Description: * Patients who are rRT-PCR negative for COVID-19

Measure: Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*

Time: Day 7

Secondary Outcomes

Measure: Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline

Time: Day 3, 7, 10, 14

Description: * Patients who are rRT-PCR negative for COVID-19

Measure: Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*

Time: Day 3, 10, 14

Measure: Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline

Time: Day 3, 7, 10, 14, 28

Measure: Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline

Time: Day 3, 7, 10, 14, 28

Measure: Time to achieve normalization of body temperature, post-dose

Time: Day 3, 7, 10, 14, 28

Measure: Time to achieve normalization of respiratory rate, post-dose

Time: Day 3, 7, 10, 14, 28

Measure: Time to achieve normalization of oxygen saturation, post-dose

Time: Day 3, 7, 10, 14, 28


No related HPO nodes (Using clinical trials)